Mineralys Therapeutics, Inc. MLYS 深 沪
交易中 08-05 11:19:08 美东时间
13.34
+0.310
+2.38%
华盛通- 最 高13.37
- 今 开12.94
- 成交量 20.39万股
- 最 低 12.93
- 昨 收 13.03
- 总市值 8.69亿
- 52周最高 18.38
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.241
- 委 比 -96.49%
- 总股本 6517.53万
- 历史最高 21.98
- 量 比 1.11
- 振 幅 3.38%
- 历史最低 5.85
- 每 手 1
- 风险率 1.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Mineralys Therapeutics计划在2025年8月12日发布其2025年第二季度财务报告，并在收盘后召开会议。会议时间为下午4:30 ET，提供电话和网络直播参与方式。公司专注于开发治疗高血压及其相关并发症的药物，其候选药物lorundrostat是一种醛固酮合成酶抑制剂。 Mineralys Therapeutics将在2025年8月12日收盘后发布第二季度财务报告，并召开会议，提供电话和网络直播参与方式。
08-04 20:05
Mineralys' Lorundrostat Achieves Clinically Meaningful Blood Pressure Reductions In Landmark Phase 3 Launch-HTN Trial; Results Published In JAMA
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension –– Lorundrostat 50 mg once daily demonstrated clinically
06-30 23:20
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
<p><strong>Summary:</strong> The Phase 3 Launch-HTN trial, published in JAMA, demonstrates that lorundrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension. At 50 mg once daily, it achieved a 16.9 mmHg reduction at Week 6 and 19.0 mmHg at Week 12, with a favorable safety profile and minimal adverse effects. Lorundrostat holds promise as a bes...
06-30 15:17
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
全球高血压用药史转折点：40年首个新靶点药物III期成功
来源：远川研究所 创新药，可以是资本市场一时的热点，但资本市场的聚光灯总是追逐着最耀眼的那一刻，而往往会忽视了那些引发股价飙升的“热点时刻”，其...
06-17 21:13
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
Mineralys Therapeutics announced positive topline results from its Phase 2 Explore-CKD trial, showing Lorundrostat achieved a significant reduction in systolic blood pressure (9.3 mmHg, p=0.0024) and urine albumin-to-creatinine ratio (31%, p<0.0001) in subjects with hypertension and CKD. The trial demonstrated a favorable safety profile, with minimal adverse events. These results support Lorundrostat's potential for treating hypertension and CKD,...
06-17 11:00
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Jefferies Initiates Coverage On Mineralys Therapeutics with Hold Rating, Announces Price Target of $15
Jefferies analyst Dennis Ding initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Hold rating and announces Price Target of $15.
06-11 19:58
Mineralys Therapeutics shares are trading higher after the company announced it will present data from its Phase 3 Launch-HTN trial evaluating the efficacy and safety of Lorundrostat at ESH 2025.
Mineralys Therapeutics shares are trading higher after the company announced it...
05-21 02:36
